Sanofi's New Cancer Drug Could Help Deliver a Big Payday

Sanofi's rilzabrutinib performed well in its phase 3 clinical trial, meaning the company can now apply for approval. The drug is a type of BTK inhibitor that combats disorders found in B lymphocytes, also known as B cells. BTK inhibitors have shown effectiveness as a treatment for such diseases as non-Hodgkin lymphomas.